PBAC's latest decision on Propranolol: Not recommended (2017). Considered for Treatment of proliferating infantile hemangioma requiring systemic therapy, including life-threatening hemangioma, ulcerated hemangioma with pain and/or lack of response to simple wound care measures, and hemangiomas with a risk of permanent scars or disfigurement.
PBAC outcome
Not recommended
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
3
first 2015
Submissions
3
2015 → 2017
Eligible population
Infants with proliferating infantile hemangioma requiring systemic therapy
Therapy area
Other
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
Auspman propranolol solution and compounded propranolol liquid
Economic model
Cost-minimisation
ICER note
Cost consequence analysis; no ICER calculated. Economic evaluation focused on pricing comparison rather than cost-effectiveness ratio.
Why PBAC said no
Reasons cited in the latest PSD: unsubstantiated cost consequence method, unacceptably high proposed price, unjustified price advantage over compounded propranolol liquid, inappropriate attribution of costs to quality assurance and risk minimisation measures, adequate access to alternative therapies
Submission history
Mar 2015: Recommended with restriction · Authority Required